Amussen Hunsaker Associates LLC Bluebird Bio, Inc. Transaction History
Amussen Hunsaker Associates LLC
- $645 Million
- Q2 2024
Shares
2 transactions
Others Institutions Holding BLUE
# of Institutions
161Shares Held
80MCall Options Held
525KPut Options Held
634K-
Black Rock Inc. New York, NY15.4MShares$7.26 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$4.84 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN6.39MShares$3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.15MShares$2.42 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V84.67MShares$2.19 Million0.02% of portfolio
About bluebird bio, Inc.
- Ticker BLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,121,800
- Market Cap $36.2M
- Description
- bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...